(Total Views: 600)
Posted On: 10/01/2020 8:25:57 PM
Post# of 148936
A buyout of the Vyera contract seems to me to likely be an imperative in any licensing deal for the US market.
As you said, blafarm:
Maybe there has been some interest by licensing partners in buying out the Vyera contract. With Vyera having the FTC lawsuit and possibly a subsequent huge financial penalty hanging over their head I could see them taking the easy cash/stock.
As you said, blafarm:
Quote:
as Dr.NP noted, the Vyera pricing structure presents a problem. The big question is -- if Vyera pricing precludes piecemeal partnering and licensing of individual indications, then what exactly are they talking about with those 11 Big Pharma companies?
Maybe there has been some interest by licensing partners in buying out the Vyera contract. With Vyera having the FTC lawsuit and possibly a subsequent huge financial penalty hanging over their head I could see them taking the easy cash/stock.
(4)
(0)Scroll down for more posts ▼
